News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medivir AB (MVIRb.F)’s Partner Tibotec Announced that Final SVR24 Results from Phase IIb PILLAR Study of TMC435 will be Presented at the AASLD Meeting Today


11/7/2011 7:30:41 AM

HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News:

Medivir AB (STO:MVIR), the research-based specialty pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced that safety and efficacy results from the phase IIb PILLAR study of once-daily TMC435 in treatment-naïve patients infected with hepatitis C will be presented as an oral late-breaker at the AASLD meeting in San Francisco, USA today.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES